On Friday, Aquestive Therapeutics Inc (NASDAQ: AQST) opened lower -4.32% from the last session, before settling in for the closing price of $3.47. Price fluctuations for AQST have ranged from $2.24 to $6.23 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -0.52% annually for the last half of the decade. Company’s average yearly earnings per share was noted -235.60% at the time writing. With a float of $80.69 million, this company’s outstanding shares have now reached $91.18 million.
In an organization with 135 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 69.39%, operating margin of -35.83%, and the pretax margin is -59.58%.
Aquestive Therapeutics Inc (AQST) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Aquestive Therapeutics Inc is 14.89%, while institutional ownership is 45.14%. The most recent insider transaction that took place on Nov 26 ’24, was worth 214. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $4.87, taking the stock ownership to the 0 shares. Before that another transaction happened on Mar 15 ’24, when Company’s Chief Innovation/Tech Officer sold 50,000 for $6.00, making the entire transaction worth $300,000. This insider now owns 984,476 shares in total.
Aquestive Therapeutics Inc (AQST) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -235.60% per share during the next fiscal year.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Check out the current performance indicators for Aquestive Therapeutics Inc (AQST). In the past quarter, the stock posted a quick ratio of 5.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.57 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Let’s dig in a bit further. During the last 5-days, its volume was 4.24 million. That was better than the volume of 1.86 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 77.49%. Additionally, its Average True Range was 0.20.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 15.36%, which indicates a significant decrease from 59.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.97% in the past 14 days, which was higher than the 63.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.40, while its 200-day Moving Average is $3.82. However, in the short run, Aquestive Therapeutics Inc’s stock first resistance to watch stands at $3.47. Second resistance stands at $3.61. The third major resistance level sits at $3.69. If the price goes on to break the first support level at $3.25, it is likely to go to the next support level at $3.17. The third support level lies at $3.03 if the price breaches the second support level.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are currently 91,178K shares outstanding in the company with a market cap of 302.72 million. Presently, the company’s annual sales total 50,580 K according to its annual income of -7,870 K. Last quarter, the company’s sales amounted to 13,540 K and its income totaled -11,510 K.
